Featured Research

from universities, journals, and other organizations

Vaccine May Protect Babies From Lethal Infection

Date:
September 21, 2005
Source:
Medical College of Georgia
Summary:
Common bacteria that live harmlessly in the gastrointestinal tract and vagina of 25 percent of women can become lethal if a newborn gets exposed to them during birth.

Dr. Daron Ferris is a principal investigator on a National Institutes of Health study of a vaccine against group B streptococcus, a common vaginal infection that can be deadly to newborns. (Phil Jones photo)

Common bacteria that live harmlessly in the gastrointestinal tract and vagina of 25 percent of women can become lethal if a newborn gets exposed to them during birth.

Researchers are studying a vaccine that may one day eliminate that risk.

“If we could give a vaccine to prevent women from harboring group B streptococcus in the vagina, then babies are not going to get it,” says Dr. Daron Ferris, family medicine physician at the Medical College of Georgia and a principal investigator on a National Institutes of Health study to explore that potential.

MCG as well as the University of Pittsburgh School of Medicine and Planned Parenthood of Houston and Southeast Texas, Inc., are enrolling a total of 600 healthy, non-pregnant women in the study.

Half the participants will get the new vaccine developed at Harvard University and the rest will receive a standard tetanus toxoid vaccine.

MCG’s participation in the study is funded by an $800,000 NIH grant. Study sites include the Augusta campus as well as the University of Georgia’s University Health Center in Athens and Georgia Southern University’s clinics in Statesboro.

The group B strep vaccine is being compared with tetanus toxoid vaccine because the tetanus vaccine, long shown to be effective, is used as the delivery mechanism for group B vaccine, Dr. Ferris says. “It’s piggy-backed onto the tetanus toxoid vaccine so the body makes antibodies to the tetanus and group B strep,” he says.

Group B strep is the most common infectious cause of death in newborns, according to the Centers for Disease Control and Prevention. Problems typically surface within the first week of life when the immune system is immature and least able to fight off infection. Results may include overwhelming infection called septicemia, meningitis, pneumonia and long-term damage such as hearing loss, impaired vision and developmental problems.

The bacteria come and go in most women, infecting about 25 percent at any one time and – for unclear reasons – a higher percentage of black women and non-smokers, Dr. Ferris says. A Pittsburgh study of predictors of infection showed that sexual activity, in terms of frequency and/or number of partners, was highly associated with vaginal infection. Also, women with an imbalance in the protective bacteria that typically colonize the vagina are at increased risk.

The bacteria usually are harmless outside the bloodstream, so physicians usually don’t screen for them or give antibiotics unless the woman is pregnant, Dr. Ferris says. In the late 1980s, physicians began testing for group B strep in the vagina and rectum at 35-37 weeks of gestation and administering an antibiotic to those who have it. The idea is that the bacteria is eliminated before the baby is born, Dr. Ferris says.

That approach has led to a dramatic decline in infection but has not eliminated it.

Problems with current prevention protocols include premature delivery and a negative test at 35 weeks gestation with subsequent infection, Dr. Ferris says.

Still, rates of group B strep disease have dropped from a high of about 2 percent of 100 live births to about .5 percent, a rate that has held for several years, according to the CDC. The infection rate is about .8 percent for black newborns. Current estimates are that 1,720 newborns are infected annually and 70-90 babies die.

The SPIN study – Streptococcal Prevention In Non-Pregnant women – aims to reduce that number by helping women eliminate the bacteria before they become pregnant.

The study will compare group B infection rates in those receiving the new vaccine to those receiving only the tetanus vaccine, who will serve as controls for this study, Dr. Ferris says. Antibody levels to group B strep also will be measured over the 18-month study to see if they go up and stay elevated for an extended period. Phase one studies, conducted in pregnant women, showed the vaccine to be safe and resulted in high levels of antibodies in the mothers that were transferred to the fetus.

How long the protection lasts will help determine how the vaccine eventually is used, says Dr. Ferris. If it provides high levels of long-term protection, it could be recommended for all young women, which would help ensure protection in unplanned pregnancies. “If it’s just say three to five years, we likely would need to target women who are interested in getting pregnant,” he says.

The study is enrolling sexually active women age 18-40 using effective birth control. Partipants will be followed every two months for 18 months, receive a free physical and pelvic exam and be compensated for their participation.


Story Source:

The above story is based on materials provided by Medical College of Georgia. Note: Materials may be edited for content and length.


Cite This Page:

Medical College of Georgia. "Vaccine May Protect Babies From Lethal Infection." ScienceDaily. ScienceDaily, 21 September 2005. <www.sciencedaily.com/releases/2005/09/050921080746.htm>.
Medical College of Georgia. (2005, September 21). Vaccine May Protect Babies From Lethal Infection. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/09/050921080746.htm
Medical College of Georgia. "Vaccine May Protect Babies From Lethal Infection." ScienceDaily. www.sciencedaily.com/releases/2005/09/050921080746.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins